About: Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients
Creator	Balgera, Roberto Basilico, Paola Cordano, Christian Mantero, Vittorio Salmaggi, Andrea Abate Md, Lucia
Source	Elsevier; Medline; PMC
abstract	INTRODUCTION: Italy has been the first European country severely affected by the COVID-19 pandemic. OBJECTIVE: To analyze the incidence of the clinical presentations suggestive for COVID-19 infection among patients with Multiple Sclerosis in the province of Lecco, in the North Italy, the closest province capital to Bergamo. To describe the association of demographics, clinical characteristics, and use of DMTs categories with the risk of contracting the disease. METHODS: We telephonically interviewed all the 275 MS patients followed in the MS center. The collected data included recent contact with a patient with COVID-19 diagnosis or a subject with respiratory symptoms and the developing of COVID-19 symptoms or a confirmed diagnosis. RESULTS: 15 out of 275 patients reported symptoms suggestive for COVID-19 infection, only one of them with PCR-confirmed diagnosis. No one of them presented severe symptoms or needed hospitalization. Using a multivariable logistic regression model, the only factor associated with being in the COVID-suspect group was the report of a recent contact with a patient with a COVID-19 diagnosis. CONCLUSIONS: The prevalence of COVID-19 within MS patients seems to resemble the prevalence in general population. The lack of associations with other factors assessed, including DMTs, may reflect a lack of statistical power. Larger population studies are needed to explore the correlation between different disease-modifying therapies and COVID-19 course.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1016/j.msard.2020.102453
bibo:pmid	32835900
has license	no-cc
sha1sum (hex)	85925b4ed88e6642e5c9376ad80c825a2c013f49
schema:url	https://doi.org/10.1016/j.msard.2020.102453
resource representing a document's title	Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients
has PubMed Central identifier	PMC7434623
has PubMed identifier	32835900
schema:publication	Mult Scler Relat Disord
resource representing a document's body	covid:85925b4ed88e6642e5c9376ad80c825a2c013f49#body_text
is schema:about of	covid:arg/85925b4ed88e6642e5c9376ad80c825a2c013f49 named entity 'multiple sclerosis' named entity 'European' named entity 'COVID-19' named entity 'multiple sclerosis' named entity 'COVID' named entity 'interferons' named entity 'DMT' named entity 'COVID' named entity 'sore throat' named entity 'COVID' named entity 'province of Lecco' named entity 'demographic' named entity 'DMT' named entity 'neurologist' named entity 'DMT' named entity 'sample size' named entity 'infection' named entity 'general population' named entity 'harmful effects' named entity 'teriflunomide' named entity 'Como' named entity 'healthcare professional' named entity 'CIS' named entity 'Lake Como' named entity 'natalizumab' named entity 'DMTs' named entity 'EDSS' named entity 'teriflunomide' named entity 'ocrelizumab' named entity 'logistic regression' named entity 'infection' named entity 'risk factors' named entity 'clinical characteristics' named entity 'COVID' named entity 'DMT' named entity 'disability' named entity 'Lombardy' named entity 'COVID' named entity 'vomiting' named entity 'COVID-19' named entity 'runny nose' named entity 'diabetes' named entity 'COVID' named entity 'COVID-19' named entity 'sample size' named entity 'relapsing-remitting' named entity 'ageusia' named entity 'respiratory symptoms' named entity 'coronavirus disease 2019' named entity 'interferons' named entity 'inflammatory diseases' named entity 'EDSS' named entity 'COVID-19 infection' named entity 'DMF' named entity 'Bergamo' named entity 'cardiovascular disease' named entity 'alemtuzumab' named entity 'Italy' named entity 'mechanisms of action' named entity '14.1' named entity 'respiratory symptoms' named entity 'DMTs' named entity 'ISTAT' named entity 'Italian' named entity 'intubation' named entity 'cladribine' named entity 'alemtuzumab' named entity 'DMTs' named entity 'infection' named entity 'ocrelizumab' named entity 'paresthesia' named entity 'COVID' named entity 'COVID' named entity 'PPMS' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software